C67399 is a small molecule that blocks the integrin β1 binding site of TLN1, reduces the malignant behaviours of TNBC in vitro (MDA-MB-231 cell, IC50=2.0 uM).C67399 treatment significantly reduced the viability of BT549 cells.C67399 (2 uM) significantly reduced the expression of integrin β1, AKT, FAK, and phosphorylated FAK in MDA-MB-231 cells, while did not affect the expression of integrin β3.C67399 inhibited the binding of TLN1 to integrin β1 in MDA-MB-231 cells.C67399 (1.75 mg/kg) inhibited tumour growth and metastasis of MDA-MB-231 cells in mice, without causing obvious structural toxic changes.

Tubulin-IN-65 (Compound Imp-18) is a Tubulin inhibitor. Tubulin-IN-65 exhibits tubulin-disrupting activity. Tubulin-IN-65 disrupts microtubule integrity. Tubulin-IN-65 induces Apoptosis and increases the expression of CDK1 and Cyclin B1. Tubulin-IN-65 possesses anticancer activity against breast cancer and colorectal cancer. Tubulin-IN-65 can be used in research related to triple-negative breast cancer and colorectal adenocarcinoma.

SCH-602539 is a selective PAR-1 antagonist. SCH-602539 inhibits platelet aggregation in response to PAR-1-selective high-affinity thrombin receptor agonist peptide. SCH-602539 exhibits synergistic antithrombotic effects when used in combination with Cangrelor.

Sameridine (NIH-10908 free base) is a weak partial agonist of the μ-opioid receptor. Sameridine shows local anesthetic and analgesic properties. Sameridine has minimal respiratory depression at low doses, but can suppress ventilatory response at high doses. Sameridine can be used for the study of analgesic effect.

S1R agonist 3 is a potent and selective sigma-1 receptor (S1R) agonist with a Ki of 1.5 nM. S1R agonist 3 reduces hyperlocomotion in wfs1abKO zebrafish larvae without affecting locomotion in wildtype wfs1abWT zebrafish larvae. S1R agonist 3 reverses Aβ25-35-induced learning and memory impairments. S1R ligand 1 can be used for the research of Alzheimer’s disease.

Ramiprilat acyl-β-D-glucuronide is an acyl glucuronide metabolite of Ramiprilat. Ramiprilat acyl-β-D-glucuronide undergoes methylation on its glucuronic acid moiety during solid phase extraction with strong cation exchanger cartridges, forming a methylated derivative. Ramiprilat acyl-β-D-glucuronide undergoes in-source conversion to Ramiprilat in mass spectrometry, with conversion extent proportional to declustering potential voltage.

PROTAC RET Degrader 1 (Compound 20) is an orally active and blood-brain barrier-crossing RET PROTAC degrader with DC50 values for RET (WT), RET (G810S), RET (G810C), and RET (G810R) of 1.7, 3, 12, and 21 nM, respectively. PROTAC RET Degrader 1 exhibits potent anti-proliferative activity in cancer cell lines carrying oncogenic RET fusions (such as KIF5B-RET, CCDC6-RET) or mutations (such as RET (C634W)). PROTAC RET Degrader 1 shows significant anti-tumor activity in human tumor xenograft (PDX) mouse models. PROTAC RET Degrader 1 can be used for the study of RET-positive cancers Pink: RET ligand; Blue: CRBN ligand; Black: Linker).

PNU 101099 is a 50S ribosomal subunit inhibitor. PNU 101099 has antibacterial activity. PNU 101099 can be used for infection research.

PFKFB4-IN-1 is a potent and selective ATP-competitive PFKFB4 inhibitor (IC50 = 4.50 μM) that reduces intracellular PFKFB4 protein levels. PFKFB4-IN-1 exhibits >12-fold selectivity over PFKFB1/4 and PFKFB3/4. PFKFB4-IN-1 inhibits cancer cell proliferation, induces apoptosis, and inhibits cell migration. PFKFB4-IN-1 inhibits tumor growth in the MDA-MB-231 xenograft mouse model. PFKFB4-IN-1 can be used for breast, lung and liver cancer research.

LP-371-p is a lipid that can specifically and efficiently deliver oligonucleotide compounds to the fat tissues in the body (especially fat cells). LP-371-p can be used in research on diseases related to fat, such as obesity and type 2 diabetes.

Losoxantrone hydrochloride (CI 941 hydrochloride) is a DNA-binding agent. Losoxantrone hydrochloride has broad-spectrum antitumour activity. Losoxantrone hydrochloride induces dose-dependent leukopenia.

GPX4-IN-1 is a potent GPX4 inhibitor. GPX4 shows antiproliferative activity. GPX4-IN-1 has the potential for the research of cancer.

Gal-GIcNAc-oxazoline (compound 24) is an N-acetylglucosamine (GlcNAc) and azide-modified disaccharide that can be used to label antibodies. Gal-GIcNAc-oxazoline can be synthesized as an ADC via click chemistry.

FTC-146 precursor (Compound s6) is a drug intermediate that can be used to prepare σ-1 receptor positron emission tomography tracers ([¹⁸F]FTC-146).

E3 Ligase Ligand-linker Conjugate 214 is an E3 ligase ligand-linker conjugate containing a Von Hippel-Lindau (VHL) ligand and a linker. E3 Ligase Ligand-linker Conjugate 214 can bind to a target protein ligand to form a PROTAC molecule, PROTAC LSD1 Degrader 1.

Dasatinib (GMP Like) (BMS-354825 (GMP Like)) is Dasatinib produced by using GMP like guidelines. GMP Like small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Dasatinib (BMS-354825) is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity. The Kis are 16 pM and 30 pM for Src and Bcr-Abl, respectively. Dasatinib inhibits Bcr-Abl and Src with IC50s of <1.0 nM and 0.5 nM, respectively. Dasatinib also induces apoptosis and autophagy.

CGS 24012 (DPMA) is a selective adenosine A2 agonist. CGS 24012 produces significant increases in cardiac output. CGS 24012 reduces renal vascular resistance to the greatest extent and produces a concomitant significant increase in renal blood flow. CGS 24012 can be used in the research of hypertension.

cGAS-IN-9 is a cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS) inhibitor, with IC50 values of 27.5 nM and 5.15 μM against human and murine cGAS, respectively. cGAS-IN-9 shows weak inhibitory activity against human soluble adenylate cyclase, with an IC50 of 26.4 μM. cGAS-IN-9 inhibits dsDNA-induced expression of IFNB1 and CXCL10, as well as activation of the NF-κB pathway, in human immune cells. cGAS-IN-9 can be used in research related to cGAS-dependent inflammatory diseases.

Cenpemlin is a CENP-M inhibitor that disrupts the CENP-M/CENP-L interaction. Cenpemlin can be used for investigating centromere-kinetochore interactions and dynamic kinetochore assembly during cell division.

C8-Glucosylceramide is a glycosphingolipid.

(S,S)-SARM1-IN-9 (Compound MY-13A) is a stereoselective SARM1 inhibitor with covalent binding properties. (S,S)-SARM1-IN-9 covalently modifies Cys311 in the autoregulatory ARM domain of wild-type SARM1, thereby blocking NADase activity, without inhibiting the SARM1C311A or SARM1C311S mutants. (S,S)-SARM1-IN-9 blocks vacor- and vincristine-induced axon degeneration in primary rodent dorsal root ganglion neurons. (S,S)-SARM1-IN-9 can be used for research on axon degeneration-dependent neurological disorders, including chemotherapy-induced peripheral neuropathy.

(Rac)-UCB-J (Compound 23) is a ligand for synaptic vesicle protein 2A (SV2A), with a pIC50 value of 8.2. (Rac)-UCB-J can be used as a PET tracer for SV2A to assist in the diagnosis of epilepsy research.

(R)-SM875 is a degrader targeting the intermediate folding form of prion protein (PrP). (R)-SM875 significantly reduces the PrP level, with an IC50 of 3 μM. (R)-SM875 can be used for the study of prion diseases.

(21R)-Argatroban is a diastereoisomer of Argatroban. (21R)-Argatroban is also an inhibitor of thrombin with anticoagulant activity. (21R)-Argatroban can be used for research related to anticoagulation.

Ecad saRNA is a small activating RNA (saRNA) targeting the E-cadherin genes. Ecad saRNA induce expression of the E-cadherin genes, and targets the E-cadherin promoters at ?215 relative to gene's transcription start site.

ALN-12115 is a siRNA that targets kinesin spindle protein (KSP), and it is one of the siRNAs in ALN-VSP.ALN-VSP is a lipid nanoparticle formulation containing two siRNAs for KSP and VEGF with potential antitumor activity.

ALN-12115 sodium is a siRNA that targets kinesin spindle protein (KSP), and it is one of the siRNAs in ALN-VSP.ALN-VSP is a lipid nanoparticle formulation containing two siRNAs for KSP and VEGF with potential antitumor activity.

Emvistegrast is a quinolone derivative. Emvistegrast is an antagonist of α4β7 integrin. Emvistegrast can be studied in research for diseases that are mediated by α4β7 integrin, such as infkammatory bowel disease.

MT-228 (BPN-0026709) is a selective and blood-brain barrier permeable non-muscle myosin II inhibitor. MT-228 markedly improves tolerability by selectively targeting NMIIB (KI = 1.5 μM) over CMII (KI = 17 μM), and the sequence of SmMll MD is 83.6% identical to that of NMllB. MT-228 shows long-lasting efficacy in animal models of stimulant use disorder.

Salvianolic acid A derivative-1 (Compound SAA-30) is a orally active derivative of Salvianolic acid A. Salvianolic acid A derivative-1 binds to transgelin with a KD of 2.39 μM. Salvianolic acid A derivative-1 promotes cell contractions by facilitating the aggregation of actin. Salvianolic acid A derivative-1 can be used for prevention of myocardial ischemia or other diseases associated with IR tissue injuries.